Exact Sciences Corporation (EXAS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$104.91
Price Target
$103.18
Target Range
$85.00 — $105.00
Analyst Rating
Buy
Forward P/E582.8x
Trailing P/E-95.4x
Forward PEG—
Implied Growth+116.4%
Median Target$105.00
Analyst Spread19.4%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$85
-19.0%
Consensus
$103
-1.6%
Bull Case
$105
+0.1%
EXAS Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Exact Sciences Corporation (EXAS) has a Wall Street consensus price target of $103.18, based on estimates from 41 covering analysts. With the stock currently trading at $104.91, this represents a potential downside of -1.6%. The company has a market capitalization of $20.02B.
Analyst price targets range from a low of $85.00 to a high of $105.00, representing a 19% spread in expectations. The median target of $105.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, EXAS trades at a trailing P/E of -95.4x and forward P/E of 582.8x. Analysts expect EPS to grow +116.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+23.7%
Avg Forward P/E21.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GHGuardant Health, Inc. | $12.1B | $92.26 | $133.14 | +44.3% | Buy | — | 30 |
 NTRANatera, Inc. | $31.2B | $219.82 | $262.50 | +19.4% | Buy | — | 27 |
 ILMNIllumina, Inc. | $21.1B | $138.71 | $147.38 | +6.3% | Buy | 26.8x | 50 |
 LHLabcorp Holdings Inc. | $21.2B | $258.04 | $311.33 | +20.7% | Buy | 14.5x | 35 |
 DGXQuest Diagnostics Incorporated | $21.1B | $190.84 | $220.57 | +15.6% | Hold | 17.8x | 34 |
 NEOGNeogen Corporation | $2.0B | $9.25 | $11.00 | +18.9% | Hold | 25.9x | 11 |
 CDNACareDx, Inc | $1.1B | $21.44 | $24.00 | +11.9% | Buy | 22.8x | 13 |
 TMOThermo Fisher Scientific Inc. | $176.4B | $474.56 | $654.67 | +38.0% | Buy | 19.1x | 42 |
 DHRDanaher Corporation | $124.3B | $175.66 | $247.00 | +40.6% | Buy | 20.8x | 42 |
 BIOBio-Rad Laboratories, Inc. | $6.9B | $257.32 | $312.50 | +21.4% | Buy | 25.0x | 14 |
Upside Potential Comparison
GHDHRTMOBIOLHNTRANEOGDGXFull EXAS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See EXAS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EXAS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EXAS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEXAS — Frequently Asked Questions
Quick answers to the most common questions about buying EXAS stock.
What is the EXAS stock price target for 2026?
Wall Street's consensus price target for EXAS is $103.18, -1.6% from its current price of $104.91. The below-market target from 41 analysts suggests limited near-term appreciation.
Is EXAS a buy, sell, or hold?
EXAS has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $103.18 implies -1.6% downside from current levels.
Is EXAS stock overvalued or undervalued?
At a forward P/E of 582.8333x, EXAS trades at a premium valuation. The consensus price target of $103.18 (-1.6% downside) suggests analysts may view current valuations as stretched.
How high can EXAS stock go?
The most bullish Wall Street analyst has a price target of $105 for EXAS, while the most conservative target is $85. The consensus of $103.18 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover EXAS stock?
EXAS is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the EXAS stock forecast?
The 12-month EXAS stock forecast based on 41 Wall Street analysts shows a consensus price target of $103.18, with estimates ranging from $85 (bear case) to $105 (bull case). The median consensus rating is "Buy".
What is EXAS's forward P/E ratio?
EXAS trades at a forward P/E ratio of 582.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy EXAS stock?
Analysts are cautious on EXAS, with 2 Sell ratings and a price target of $103.18 (-1.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do EXAS price targets vary so much?
EXAS analyst price targets range from $85 to $105, a 19% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $103.18 consensus represents the middle ground.